Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HLX02 vs Herceptin in Healthy Chinese Males
NCT04670796Phase 1Completed
- Sponsor
- Henlius
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab in HER2-positive breast cancer and gastric cancer (GC) (3 arms), sponsored by Henlius. Primary endpoint: Area under the concentration-time curve from time zero to infinity at 57 days. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT04670796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670796.